Bli medlem
Bli medlem

Du är här


Nexstim Oyj: Nexstim Plc pre-close business update

Press release, Helsinki, 22 December 2016, at 12pm

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim
" or "Company
"), a medical technology company with a pioneering navigated non-invasive
brain stimulation system, today announces a business update for the year
ending 31 December 2016.

Navigated Brain Stimulation

Customer adoption of Navigated Brain Stimulation (NBS) systems for brain
mapping is increasing and current users continue to adopt and incorporate the
technology into their clinical practice. New customers at various prestigious
institutions, world-wide purchasing the technology include: The University of
Iowa; Dell Children's Hospital in Austin, Texas; Vivantes Klinikum Neukölln
in Germany; Queen Elizabeth Hospital Birmingham in UK, and; Aarhus University
Hospital in Denmark.

The NBS technology was highlighted in multiple clinical presentations at
various scientific congresses including: Society for Neuro-Oncology Annual
Meeting; 8thInternational Symposium on Navigated Brain Stimulation in
Neurosurgery and Neuromodulation; Congress of Neurological Surgeons Annual
Meeting; Deutsche Gesellschaft für Neurochirurgie; 20thScandinavian Course in
Neurosurgery; European Association of Neurosurgical Societies Congress;
10thMeeting of the European Low Grade Glioma Network; American Epilepsy
Society Meeting, and; American Association of Neurological Surgeons Annual

In line with the Company's strategic direction, progress is being made to
partner with independent distributors in the U.S. to advance commercial
efforts for Nexstim's NBS for brain mapping.

Navigated Brain Therapy

As separately announced yesterday, Nexstim received a positive response and
comments from the US Food and Drug Administration on its limited size trial
protocol for the proposed Post-Stroke Motor Recovery Trial. The positive
response paves the way for a new 60 patient trial with Nexstim's Navigated
Brain Therapy (NBT®) in 2017 and Nexstim expects to receive de novo 510(k)
clearance in Q4 2018.

In Europe, commercial steps are being conducted around NBT®, working with
early adopter clinicians.


The financing arrangement in the form of a joint deal with Bracknor and Sitra
continues on track. Since the beginning of the arrangement announced on 18
August 2016, Nexstim has issued new shares worth EUR 7.7 million in total.
The current cash and cash generated from sales, the financing arrangements
with Bracknor and Sitra, combined with the strategic changes in the
organisation, is estimated to finance the Company until early 2018.

The full year 2016 financial results will be published on Tuesday, February
28, 2017.

Commenting on the business update, Martin Jamieson, CEO of Nexstim, said:
"2016 has been a very important year for the Company with significant clinical
and financial developments. We continue to make good progress in many key
areas and look forward to moving these forward in 2017."

Martin Jamieson, CEO

Further information is available on the website
www.nexstim.comor by telephone:


Martin Jamieson, CEO

UB Securities Oy
(Certified Adviser)
+358 (0)9 2538 0246

Consilium Strategic Communications
+44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Laura Thornton

About Nexstim Plc

Nexstim is a medical technology company which has pioneered its technology in
brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is
the first and only FDA cleared and CE marked system based on navigated
Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the
speech and motor cortices of the brain. Based on the same technology
platform, the Company has developed a system called Navigated Brain Therapy
(NBT®) which is CE marked for the treatment of chronic neuropathic pain,
major depression and stroke. Nexstim shares are listed on the Nasdaq First
North Finland and Nasdaq First North Sweden. For more information please

Nexstim Plc

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.